Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
01-03 May, 2026
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
01-03 May, 2026
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Digital content

20 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/20/3276859/0/en/monte-rosa-therapeutics-presents-preclinical-data-at-american-association-for-cancer-research-aacr-annual-meeting-2026-on-the-potential-of-its-cyclin-e1-ccne1-directed-molecular-gl.html

17 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/17/3256993/0/en/Monte-Rosa-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates.html

16 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/16/3256118/0/en/Monte-Rosa-Therapeutics-Announces-Clinical-Supply-Agreement-to-Support-Phase-2-Trial-Evaluating-MRT-2359-in-Combination-with-Apalutamide-for-the-Treatment-of-Metastatic-Castration-.html

24 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/24/3243353/0/en/Monte-Rosa-Therapeutics-Presents-Updated-Clinical-Data-from-Phase-1-2-Study-of-MRT-2359-in-Combination-with-Enzalutamide-in-Heavily-Pretreated-Metastatic-Castration-Resistant-Prost.html

23 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/23/3242475/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

07 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/07/3214388/0/en/Monte-Rosa-Therapeutics-Announces-Positive-Interim-Phase-1-Data-of-MRT-8102-Demonstrating-Profound-CRP-Reductions-in-Elevated-CVD-risk-Subjects.html
ABOUT THIS PAGE